Skip to main content

Table 4 Mean Hb reduction between days 0 and 7 by G6PD status and treatment arm

From: Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania

Characteristic

Treatment arm

AL

AL + PQ

A: Mean absolute and relative Hb reduction by phenotypic G6PD status

Mean absolute Hb reduction (g/dL) (95 % CI)

G6PD normal

0.83 (0.57–1.10)

0.81 (0.59–1.02)

G6PD deficient

0.88 (0.32–1.45)

1.16 (0.67–1.66)

P value

0.87

0.23

Mean relative Hb reduction (%) (95 % CI)

G6PD normal

6.4 (4.29–8.56)

7.2 (5.04–9.35)

G6PD deficient

7.8 (4.23–11.36)

7.9 (4.58–11.18)

P value

0.71

0.16

B: Mean absolute and relative Hb reduction by genotypic G6PD status

Mean absolute Hb reduction (g/dL) (95 % CI)

G6PD wild-type/normal

0.82 (0.56–1.1)

0.74 (0.52–0.95)

G6PD heterozygous

1.68 (0.87–2.51)

1.27 (0.56–1.99)

P value

0.048

0.09

G6PD hemizygous/homozygous

0.35 (−0.36–1.1)

1.48 (0.59–2.37)

P value

0.21

0.047

Mean relative Hb reduction (%) (95 % CI)

G6PD wild-type/normal

6.8 (4.67–8.96)

6.2 (4.25–8.17)

G6PD heterozygous

14.3 (7.02–21.55)

10.9 (5.10–16.87)

P value

0.045

0.09

G6PD hemizygous/homozygous

2.7 (4.22–9.68)

12.6 (6.0–19.25)

P value

0.21

0.059